A ceremony marking the start of construction on AstraZeneca's new small molecule drug factory is held in Wuxi, East China's Jiangsu province, on May 8. [Photo provided to chinadaily.com.cn] ...

Darren Sissons' Top Picks: AstraZeneca, Canadian Pacific Kansas City & Linde Plc Darren Sissons, partner and portfolio manager at Campbell, Lee & Ross Investment Management, shares his top stock picks ...

On May 8, 2025, the Court of Appeals for the Third Circuit affirmed the district court’s dismissal of AstraZeneca’s challenges to the Inflation Reduction Act’s Drug Price Negotiation Program ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing ...

The latest design in Bernews’ weekly Wallpaper Wednesday series features three pink high heel shoes decorated with the letters ‘BDA’ set against a soft pink background. The design is ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Domestic ...

So on that alone, maybe yes. But what might this new US move mean for the industry overall, and for AstraZeneca shares specifically? Analyst Stefan Schneider at Bank Vontobel said it “has the ...

We really understood each other.' Laura May Todd, Wallpaper's Milan Editor, based in the city, is a Canadian-born journalist covering design, architecture and style. She regularly contributes to a ...

A ceremony marking the start of construction on AstraZeneca's new small molecule drug factory is held in Wuxi, East China's Jiangsu province, on May 8. [Photo provided to chinadaily.com.cn ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non ...

(Alliance News) - AstraZeneca PLC on Friday said it has received positive data from a trial evaluating Imfinzi as a treatment for patients with high-risk non-muscle-invasive bladder cancer.

Drugmakers said it could cost them $1 trillion over the next decade. A U.S. appeals court shut down AstraZeneca’s challenge to the U.S. government program that gives Medicare the power to ...